← Back to Search

Heparin Analog

Dociparstat for Acute Myeloid Leukemia (AML Trial)

Phase 3

Waitlist Available

Research Sponsored by Chimerix

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up measured from randomization up to 5 years

Awards & highlights

AML Trial Summary

This trial is testing a new drug to treat AML, a blood cancer.

Eligible Conditions

Acute Myeloid Leukemia

AML Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ measured from randomization up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~measured from randomization up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and measured from randomization up to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Overall Survival

Secondary outcome measures

Event free survival

AML Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: DociparstatExperimental Treatment1 Intervention

Treatment with standard intensive induction, reinduction, or consolidation chemotherapy and dociparstat 4 mg/kg intravenous (IV) bolus on Day 1, administered 30 minutes after completion of the first dose of idarubicin or daunorubicin, followed by dociparstat 0.25 mg/kg/hr via continuous IV infusion 24 hours daily for 5 or 7 days.

Group II: ControlPlacebo Group1 Intervention

Treatment with standard intensive induction, reinduction, or consolidation chemotherapy and placebo intravenous (IV) bolus on Day 1, administered 30 minutes after completion of the first dose of idarubicin or daunorubicin, followed by placebo via continuous IV infusion 24 hours daily for 5 or 7 days.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

ChimerixLead Sponsor

41 Previous Clinical Trials

4,130 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

If I wanted to enroll in this research project, how many different places would have it available?

"The trial is being conducted out of 11 total sites, which include University of Kansas Cancer Center in Westwood, Kansas, UC Irvine Medical Center in Orange, California, and Baylor in Dallas, Texas."

Answered by AI

What are some primary conditions that Dociparastat sodium is used to treat?

"Dociparastat sodium is most often used to treat patients with medical devices, however, the medication can also help those suffering from atrial fibrillation, sprains, and unstable angina pectoris."

Answered by AI

What is the historical research on Dociparastat sodium?

"Dociparastat sodium was first researched in 2006 by Bayview Nephrology, Inc. Since then, there have been 18449 additional studies completed. Right now, there are 45 ongoing studies, with a high concentration in Westwood, Kansas."

Answered by AI

What is the potential toxicity of Dociparastat sodium?

"There is some clinical evidence to support the efficacy of Dociparastat sodium and it has been through multiple rounds of safety testing, so it received a score of 3."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Dociparstat in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia

2021. "Dociparstat in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04571645.